Protalix BioTherapeutics Inc (PLX) Q4 2025 Earnings Call Highlights: Strategic Advances and ... [Yahoo! Finance]
Protalix BioTherapeutics, Inc. (DE) (PLX)
NASDAQ:AMEX Investor Relations:
phx.corporate-ir.net/phoenix.zhtml?c=101161&p=irol-irhome
Company Research
Source: Yahoo! Finance
This article first appeared on GuruFocus Release Date: March 18, 2026 For the complete transcript of the earnings call, please refer to the full earnings call transcript Positive Points The European Commission approved a new dosing regimen for EFrio, enhancing treatment options for Fabry disease patients in the EU. Protalix BioTherapeutics Inc ( PLX ) received a EUR25 million milestone payment following the EU approval, boosting their financial position. Projected cash balance of approximately $50 million by early April 2026, providing strong financial flexibility. Expected revenue growth of over 50% in 2026, driven by increased patient numbers and milestone payments. Advancement of PRX 115 in the pipeline, with phase 2 trials underway, indicating strong momentum in R&D. Negative Points Net loss of $6.6 million recorded for 2025, compared to a net income of $2.9 million in 2024, reflecting increased R&D investments. R&D expenses increased by 51% year over year,
Show less
Read more
Impact Snapshot
Event Time:
PLX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PLX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PLX alerts
High impacting Protalix BioTherapeutics, Inc. (DE) news events
Weekly update
A roundup of the hottest topics
PLX
News
- Protalix BioTherapeutics (PLX) had its "buy" rating reaffirmed by HC Wainwright. They now have a $12.00 price target on the stock.MarketBeat
- Protalix BioTherapeutics advances Fabry disease and gout programs during 2025 [Yahoo! Finance]Yahoo! Finance
- Protalix BioTherapeutics Reports Fiscal Year 2025 Financial and Business ResultsPR Newswire
- Protalix BioTherapeutics FY Earnings Preview [Seeking Alpha]Seeking Alpha
- Protalix BioTherapeutics to Announce Fiscal Year 2025 Financial Results and Business Update on March 18, 2026PR Newswire
PLX
Earnings
- 3/18/26 - Miss
PLX
Analyst Actions
- 3/19/26 - HC Wainwright
PLX
Sec Filings
- 3/18/26 - Form 10-K
- 3/18/26 - Form 8-K
- 3/9/26 - Form 8-K
- PLX's page on the SEC website